Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”The first generation of hemophilia A gene therapies changed the field in an important way.
The question is no longer simply whether gene therapy can reduce bleeding.
The question is whether gene therapy can deliver durable expression over time.
Patients remain highly interested in gene therapy, but long-term durability has become central to adoption decisions for both patients and providers.
At GeneVentiv, this understanding shaped the design and program development of GENV-HEM (AAV8.FVa), which leverages native hepatic biology associated with Factor V expression.
Importantly, our vision for the future of hemophilia A gene therapy includes inhibitor patients.
Patient decisions to adopt gene therapy will ultimately be made not just by efficacy, but by durability.”
Stay updated with Hemostasis Today.
-
May 14, 2026, 17:17Abhijit D: Reticulocyte Count Methods in Hematology Laboratories
-
May 14, 2026, 16:46Michele Romoli: Neurointerventional Workforce Gaps and Stroke Thrombectomy Access in Europe
-
May 14, 2026, 16:37Reyes Calzada Bau: What It Means to Live with Immune Thrombocytopenia
-
May 14, 2026, 16:34Julia Owens: Improving Acute Stroke Care for Patients Without Timely Intervention
-
May 14, 2026, 16:28Krish Patel։ Opioid Overdose and Heart-Related Deaths in the USA (1999–2023)
-
May 14, 2026, 16:26Carla Goulart Peron: 79th World Health Assembly Momentum for Global Stroke Action
-
May 14, 2026, 16:21Love Preet Kalra: Honored to Present Our Data on Plasma GFAP Measurements for ICH at ESOC 2026
-
May 14, 2026, 16:09Dino Mehic: BDUC and Its Overlap With Inherited and Rare Bleeding Disorders
-
May 14, 2026, 16:06Silvia Escribano Serrat: Flow Cytometric Osmotic Fragility Testing for Diagnosis of Hereditary Spherocytosis